Article
Chemistry, Multidisciplinary
Chunying Li, Yilin Wan, Yifan Zhang, Lian-Hua Fu, Nicholas Thomas Blum, Run Cui, Boda Wu, Rui Zheng, Jing Lin, Zhiming Li, Peng Huang
Summary: The passage discusses a starvation/chemodynamic therapeutic gel developed to combat residual IDH1 (R132H) tumor cells after surgery, showing higher therapeutic efficacy towards IDH1 (R132H) cells compared to IDH1 (WT) cells and achieving long-term survival through catalyzing oxidation processes to kill cells.
ADVANCED MATERIALS
(2022)
Article
Oncology
Mark P. van Opijnen, C. Mircea S. Tesileanu, Linda Dirven, Pim B. van der Meer, Maarten M. J. Wijnenga, Arnaud J. P. E. Vincent, Marike L. D. Broekman, Hendrikus J. Dubbink, Johan M. Kros, Sjoerd G. van Duinen, Marion Smits, Pim J. French, Martin J. van den Bent, Martin J. B. Taphoorn, Johan A. F. Koekkoek
Summary: IDHwt hLGG patients and IDHwt glioblastoma patients have similar incidence proportions of epilepsy during the entire disease course. However, the former has a significantly higher incidence of epilepsy before diagnosis and a significantly longer time between first seizure and diagnosis, indicating a distinct clinical course between the two subtypes.
Article
Medicine, General & Internal
Yin Ping Wong, Roziasyazni Che Abdul Aziz, Azimatun Noor Aizuddin, Muhamad Fakhri Mohd Saleh, Roslina Mohd Arshad, Geok Chin Tan
Summary: Accumulating data suggests that EZH2 and IDH1 are involved in promoting tumourigenesis in gliomas. This study aimed to explore the immunoexpression of EZH2 in gliomas and its correlation with clinicopathological variables. The study found that high EZH2 expression was significantly associated with older age, higher tumour grade, negative IDH1 R132H expression, shorter 5-year progression-free survival and overall survival. In IDH1 R132H-negative gliomas, high EZH2 expression was associated with shorter 5-year progression-free survival and overall survival.
Article
Oncology
Thomas K. Sears, Kevin D. Woolard
Summary: This study revealed that high expression of BRD4 is associated with decreased survival in glioma patients carrying IDHmut. Gliomas with IDHmut show increased sensitivity to the BET inhibitor JQ1, especially in terms of delayed cytotoxicity. Epigenetic-targeting drugs may serve as effective therapeutic strategies for IDHmut gliomas.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Kaishi Satomi, Akihiko Yoshida, Yuko Matsushita, Hirokazu Sugino, Kenji Fujimoto, Mai Honda-Kitahara, Masamichi Takahashi, Makoto Ohno, Yasuji Miyakita, Yoshitaka Narita, Yasushi Yatabe, Junji Shibahara, Koichi Ichimura
Summary: This study established a quantitative analysis method for the IDH1 R132H mutation using dPCR and set a quantitation limit of 0.25%. In clinical settings, dPCR analysis can validate immunohistochemistry results, even when conventional DNA sequencing fails to detect the mutation, ensuring diagnostic quality.
BRAIN TUMOR PATHOLOGY
(2022)
Article
Neurosciences
Umma Habiba, Hirokazu Sugino, Roumyana Yordanova, Koki Ise, Zen-ichi Tanei, Yusuke Ishida, Satoshi Tanikawa, Shunsuke Terasaka, Ken-ichi Sato, Yuuta Kamoshima, Masahiko Katoh, Motoo Nagane, Junji Shibahara, Masumi Tsuda, Shinya Tanaka
Summary: Oligodendrogliomas are characterized by mutations in IDH1/2 genes and chromosome 1p/19q codeletion. Differentiating between IDH mutant oligodendrogliomas and astrocytomas is crucial for selecting appropriate treatments and predicting outcomes. H3K27me3 immunostaining shows high specificity and can serve as a cost-effective and reliable method for defining 1p/19q codeletion and IDH1-R132H and ATRX immunostaining, even in the absence of 1p/19q testing.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2021)
Article
Oncology
Philipp Sievers, Martin Sill, Daniel Schrimpf, Damian Stichel, David E. Reuss, Dominik Sturm, Jurgen Hench, Stephan Frank, Lenka Krskova, Ales Vicha, Michal Zapotocky, Brigitte Bison, David Castel, Jacques Grill, Marie-Anne Debily, Patrick N. Harter, Matija Snuderl, Christof M. Kramm, Guido Reifenberger, Andrey Korshunov, Nada Jabado, Pieter Wesseling, Wolfgang Wick, David A. Solomon, Arie Perry, Thomas S. Jacques, Chris Jones, Olaf Witt, Stefan M. Pfister, Andreas von Deimling, David T. W. Jones, Felix Sahm
Summary: A study identified a specific molecular class of pediatric-type malignant gliomas with EGFR amplifications or mutations, as well as H3.1 or H3.3 K27M mutations, all showing loss of H3K27me3 staining. While some tumors exhibited a bithalamic growth pattern, a significant proportion occurred in other locations.
Article
Cell Biology
Taifu Gu, Ting Yang, Jianglong Huang, Jianhua Yu, Hongxin Ying, Xinlan Xiao
Summary: This study found that IVIM-DWI is effective in differentiating glioma grading and IDH1 mutation status. By comparing factors such as cerebral blood flow, perfusion fraction, and diffusivity, it can assist in making more accurate judgments in clinical diagnosis.
Article
Oncology
Margherita Rimini, Eleonora Loi, Carles Fabregat-Franco, Valentina Burgio, Sara Lonardi, Monica Niger, Mario Scartozzi, Ilario G. Raposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Zavattari Patrizia, Andrea Casadei-Gardini
Summary: This study identified three mutation-based clusters in IDH1-mutated intrahepatic cholangiocarcinomas (IDH1m iCCAs) and demonstrated their prognostic significance.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Chemistry, Analytical
Luis Pla, Felix Sancenon, M. Carmen Martinez-Bisbal, Ricardo Prat-Acin, Inmaculada Galeano-Senabre, Marina Botello-Marabotto, Sarai Palanca-Suela, Elena Aznar, Sara Santiago-Felipe, Ramon Martinez-Manez
Summary: The study introduces a nanodevice for detecting the IDH1-R132H mutant enzyme, capable of detecting the mutant enzyme in less than 1 hour using a fluorimeter. Validated in human glioma tissue samples by standardized methods, the biosensor shows high sensitivity, specificity, and accuracy in classifying the IDH1-R132H mutational status.
SENSORS AND ACTUATORS B-CHEMICAL
(2021)
Article
Immunology
Zhirui Zeng, Chujiao Hu, Wanyuan Ruan, Jinjuan Zhang, Shan Lei, Yushi Yang, Pailan Peng, Feng Pan, Tengxiang Chen
Summary: Specific immune biomarkers and a risk model associated with IDH1 mutation gliomas were identified in this study. Glioma patients with high-risk scores showed worse survival rates and more immune cell infiltration. These findings provide guidance for prognosis evaluation and treatment of IDH1 mutation gliomas.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Feng-Min Liu, Yu-Fei Gao, Yanyan Kong, Yihui Guan, Jinsen Zhang, Shuai-Hong Li, Dan Ye, Wenyu Wen, Chuantao Zuo, Wei Hua
Summary: The SUVmax on PET can predict IDH1 mutation with high sensitivity and specificity, supported by reduced glucose consumption in IDH1 mutant gliomas, as evidenced by changes in glucose quantity and metabolic enzyme expression levels.
Article
Pathology
Amos Muench, Daniel Teichmann, Dorothee Spille, Peter Kuzman, Eilis Perez, Sven-Axel May, Wolf C. Mueller, Theodoros Kombos, Shokufe Nazari-Dehkordi, Julia Onken, Peter Vajkoczy, Georgios Ntoulias, Conceicao Bettencourt, Andreas von Deimling, Werner Paulus, Frank L. Heppner, Arend Koch, David Capper, David Kaul, Christian Thomas, Leonille Schweizer
Summary: This study identified a novel subtype of adult-type diffuse glioma with distinct molecular and clinical features. The study found that TERT promoter mutations may not be suitable as a standalone marker for glioblastoma without further morphologic or molecular signs of high-grade glioma.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Oncology
Marina da Costa Rosa, Alex Shimura Yamashita, Gregory J. Riggins
Summary: In IDH-mutant gliomas, the combination of DNA demethylating agent 5-Azacytidine and retinoic acid (atRA) can reduce cell proliferation, increase differentiation marker expression, and induce apoptosis. However, in an orthotopic mouse model, the combination did not improve survival, highlighting the need for further optimization and preclinical studies.
Article
Anatomy & Morphology
Yonghua Liu, Bingmu Fang, Xiaoning Feng, Yu Jiang, Yuxiao Zeng, Jinhong Jiang
Summary: T-cell acute lymphoblastic leukemia (T-ALL) is a clonal malignant disease with the involvement of Isocitrate Dehydrogenase 1-R123 (IDH1-R132 H) in its progression. IDH1-R132H mutation promotes T-ALL deterioration by enhancing cell proliferation and invasion, and inhibiting apoptosis. The mutation activates the Notch1 pathway to upregulate HES1 expression, downregulate PTEN expression, and trigger PI3K/AKT pathway, ultimately promoting malignant behaviors in T-ALL cells.
Article
Biochemistry & Molecular Biology
Krissie Lenting, Mohammed Khurshed, Tom H. Peeters, Corina N. A. M. van den Heuvel, Sanne A. M. van Lith, Tessa de Bitter, Wiljan Hendriks, Paul N. Span, Remco J. Molenaar, Dennis Botman, Kiek Verrijp, Arend Heerschap, Mark ter Laan, Benno Kusters, Anne van Ewijk, Martijn A. Huynen, Cornelis J. F. van Noorden, William P. J. Leenders
Article
Clinical Neurology
Rene Aquarius, Antonius de Korte, Debby Smits, Matthew Gounis, Kiek Verrijp, Leon Driessen, William Leenders, Joost de Vries
Article
Oncology
Corina N. A. M. van den Heuvel, Anne van Ewijk, Carolien Zeelen, Tessa de Bitter, Martijn Huynen, Peter Mulders, Egbert Oosterwijk, William P. J. Leenders
FRONTIERS IN ONCOLOGY
(2019)
Article
Pathology
Corina N. A. M. van den Heuvel, Diede L. Loopik, Renee M. F. Ebisch, Duaa Elmelik, Karolina M. Andralojc, Martijn Huynen, Johan Bulten, Ruud L. M. Bekkers, Leon F. A. G. Massuger, Willem J. G. Melchers, Albert G. Siebers, William P. J. Leenders
Article
Cardiac & Cardiovascular Systems
Tomas Stolen, Mingshu Shi, Martin Wohlwend, Morten A. Hoydal, Tone F. Bathen, Oyvind Ellingsen, Morteza Esmaeili
SCANDINAVIAN CARDIOVASCULAR JOURNAL
(2020)
Article
Cell Biology
Pavlo G. Gritsenko, Nader Atlasy, Cindy E. J. Dieteren, Anna C. Navis, Jan-Hendrik Venhuizen, Cornelia Veelken, Dirk Schubert, Amparo Acker-Palmer, Bart A. Westerman, Thomas Wurdinger, William Leenders, Pieter Wesseling, Hendrik G. Stunnenberg, Peter Friedl
NATURE CELL BIOLOGY
(2020)
Article
Oncology
Eva-Leonne Gottgens, Corina N. A. M. van den Heuvel, Monique C. de Jong, Johannes H. A. M. Kaanders, William P. J. Leenders, Marleen Ansems, Johan Bussink, Paul N. Span
Article
Oncology
Julia Biedermann, Matthias Preussler, Marina Conde, Mirko Peitzsch, Susan Richter, Ralf Wiedemuth, Khalil Abou-El-Ardat, Alexander Krueger, Matthias Meinhardt, Gabriele Schackert, William P. Leenders, Christel Herold-Mende, Simone P. Niclou, Rolf Bjerkvig, Graeme Eisenhofer, Achim Temme, Michael Seifert, Leoni A. Kunz-Schughart, Evelin Schroeck, Barbara Klink
Article
Oncology
Dirk van den Brand, Sanne A. M. van Lith, Jelske M. de Jong, Mark A. J. Gorris, Valentina Palacio-Castaneda, Stijn T. Couwenbergh, Mark R. G. Goldman, Inge Ebisch, Leon F. Massuger, William P. J. Leenders, Roland Brock, Wouter P. R. Verdurmen
Article
Multidisciplinary Sciences
Morteza Esmaeili, Jason Stockmann, Bernhard Strasser, Nicolas Arango, Bijaya Thapa, Zhe Wang, Andre van der Kouwe, Jorg Dietrich, Daniel P. Cahill, Tracy T. Batchelor, Jacob White, Elfar Adalsteinsson, Lawrence Wald, Ovidiu C. Andronesi
SCIENTIFIC REPORTS
(2020)
Article
Oncology
Eva-Leonne Gottgens, Marleen Ansems, William P. J. Leenders, Johan Bussink, Paul N. Span
Summary: Cell lines are widely used for research, but the lack of well-characterized cell lines poses challenges for validating published data and applying results to the clinic. A study established a database of head and neck squamous cell carcinomas (HNSCC) cell lines, providing tools for studying HNSCC disease and summarizing HPV status, p16 status, radiosensitivity, and hypoxia data. The study found a wide range of sensitivities towards hypoxia and irradiation in the cell lines with diverse characteristics.
Article
Chemistry, Multidisciplinary
Lennard J. M. Dekker, Cassandra Verheul, Nicky Wensveen, William Leenders, Martine L. M. Lamfers, Sieger Leenstra, Theo M. Luider
Summary: The R132H mutation in IDH1 is a crucial prognostic factor for glioma patients. The metabolic changes caused by this mutation were investigated using surgically obtained glioma tissues and corresponding primary cell culture models. Results showed differences in glutamate use and aerobic glycolysis between tissue samples and cell cultures, suggesting the importance of culture conditions and tumor microenvironment in maintaining in vivo metabolic situations.
Article
Oncology
Oscar Pera, Alvaro Martinez, Christian Moehler, Bob Hamans, Fernando Vega, Fernando Barral, Nuria Becerra, Rafael Jimenez, Enric Fernandez-Velilla, Jaume Quera, Manuel Algara
Summary: The purpose of this article is to validate the deep learning-based autocontouring solution integrated in syngo.via RT Image Suite VB40. The study results show that the software has good autocontouring effects and significant time savings.
ADVANCES IN RADIATION ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Morteza Esmaeili, Bernhard Strasser, Wolfgang Bogner, Philipp Moser, Zhe Wang, Ovidiu C. Andronesi
Summary: The use of spiral-out-in (SOI) trajectory for whole-brain MRSI at 7T showed increased efficiency compared to spiral-out (SO), leading to improved data quality and metabolite quantification.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2021)
Article
Oncology
Tom H. Peeters, Krissie Lenting, Vincent Breukels, Sanne A. M. van Lith, Corina N. A. M. van den Heuvel, Remco Molenaar, Arno van Rooij, Ron Wevers, Paul N. Span, Arend Heerschap, William P. J. Leenders
CANCER & METABOLISM
(2019)